View Archive

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc.

Virtual Coffee Talk: Real-World Applications of PARP, PI3K, and HER2/3 in Breast Cancer Care

Virtual Coffee Talk: Real-World Applications of PARP, PI3K, and HER2/3 in Breast Cancer Care

Friday, March 5, 2021

Live, Interactive Webcast

7:00 AM – 8:30 AM EST


The past few years have realized approvals of several new targeted drugs for breast cancer based on increased understanding of the diverse genetic etiologies underlying this disease. The use of PARP inhibitors has greatly expanded in the treatment of patients with BRCA1/2-mutated hormone receptor–positive or triple-negative breast cancer. Patients with PIK3CA-mutated hormone receptor–positive, HER2-negative advanced breast cancer, which has been associated with poor prognosis and treatment resistance, can now be treated with PI3K inhibitors. Development of anticancer therapies that target the HER2 pathway have resulted in 3 new approvals for breast cancer in less than a year. With the complexity of current genetic test information, it is critical to examine recent clinical developments of these oncogenic targeted therapies and appreciate the implications for breast cancer treatment.

In conjunction with the highly scientific programming of the 38th Annual Miami Breast Cancer Conference®, this live, interactive webcast will provide multiple perspectives on the topic in a conversational, easy-to-digest format. This activity will help health care professionals maintain a state-of-the-art clinical practice by providing expert guidance on the latest clinical data on PARP, PI3K, and HER2/3 inhibitors, as well as the potential applications for investigational oncogenic targeted therapies for breast cancer.

Benefits of Attending

  • Ask the experts how they might handle challenging clinical cases
  • Improve your knowledge about emerging oncogenic targets for treating breast cancer
  • Learn about the latest evidence on PARP, PI3K, and HER2/3 inhibitors for the treatment of different types of breast cancer
  • Gain expert perspectives on best practices for mitigating adverse events related to targeted therapies for breast cancer

Hot Topics

  • When to test for BRCA1/2, PIK3CA, or HER2/3 mutations in patients with breast cancer
  • PARP inhibitors for treatment of early-stage and advanced triple-negative breast cancer
  • Managing patients with metastatic HR+/HER2- breast cancer with PI3K inhibitors
  • How to sequence HER2-targeted therapy in patients with HER2+ metastatic breast cancer

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Merck & Co., Inc.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should have improved their ability to:

  • Review the mechanistic rationale concerning the role of targeted therapies, including PARP inhibition, PI3K inhibition, and HER2/3 inhibition in breast cancer
  • Discuss strategies to integrate novel targeted approaches for the management of patients with breast cancer
  • Safely apply treatment approaches with oral targeted therapies in patients with breast cancer by managing treatment-associated toxicities
  • Evaluate emerging data and investigational targeted therapies among patients with breast cancer based on ongoing clinical trials

Program Chair

Kevin Kalinsky, MD, MS
Kevin Kalinsky, MD, MS
Acting Associate Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Breast Medical Oncology
Director, Glenn Family Breast Center
Winship Cancer Institute of Emory University
Atlanta, GA


Registration fees include virtual conference access and e-syllabus materials.

3 Ways to Register

  1. Online: Click here.
  2. Phone: Please call +1-(888)-949-0045 or +1-(609)-378-3701 (credit cards only).
  3. Fax: +1-(609)-257-0705 (credit cards only).

Physicians' Education Resource®
2 Clarke Drive
Suite 100
Cranbury, NJ 08512

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image").  By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By